RT Journal Article
SR Electronic
T1 Ultra–short-wave diathermy shortens the course of moderate and severe COVID-19: a randomized trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.28.21250163
DO 10.1101/2021.01.28.21250163
A1 Liangjiang Huang
A1 Qian Li
A1 Shah Zulfiqar Ali Sayed
A1 Nasb Mohammad
A1 Bin Chen
A1 MPhil Ali Iftikhar
A1 Lingfeng Xie
A1 Jifa Hu
A1 Hong Chen
YR 2021
UL http://medrxiv.org/content/early/2021/03/30/2021.01.28.21250163.abstract
AB Question Is ultra-short-wave diathermy (USWD) safe and effective in coronavirus disease 2019 (COVID-19) ?Design Single-centre, evaluator-blinded, two-arm, parallel design, randomized controlled clinical trial.Participants Moderate and severe COVID-19 patients with acute respiratory syndrome.Intervention USWD for 10 minutes twice daily for 12 consecutive days along with standard medical treatment (USWD group, n = 25), versus standard medical treatment alone (control group, n = 25).Outcome measures The primary outcomes were the duration of recovery and negative conversion rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on days 7, 14, 21, and 28. Secondary outcomes included clinical status (seven-category ordinal and systemic inflammatory response syndrome (SIRS) scores), computed tomography (CT), routine blood tests, and adverse events.Results Time to clinical recovery (USWD 36.84±9.93 vs. control 43.56±12.15, P = 0.037) was significantly shortened with a between-group difference of 6.72 days. Clinical status was improved with significant between-group differences on day 28 (SIRS, P = 0.011; seven-category scale, P = 0.003). The rate of RNA negative conversion at days 7 (P = 0.066), 14 (P = 0.239), 21 (P = 0.269), and 28 (P = 0.490) was statistically insignificant. Moreover, insignificant differences were observed in the artificial intelligence-assisted CT analysis. No treatment-associated adverse events or worsening of pulmonary fibrosis were observed.Conclusion USWD, as adjunctive therapy, shortened the recovery course and improved clinical status of patients with COVID-19 without aggravating pulmonary fibrosis. the findings are limited due to the small sample size and early termination.Registration ChiCTR2000029972Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000029972Funding StatementThe study was funded by the National Key Research and Development program(NO:2020YFC08845600).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:this randomized controlled trial was approved by the ethics committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (certificate of approval number TJ-C20200127)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe trial data could be provided by a reasonable request to the corresponding authors (HC). http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000029972